ERBB2 and breast carcinoma: To compare the specific binding activity of anti-HER2 VHH-FcK to various breast cancer cells, ELISA was conducted using SK-BR-3 (HER2-positive), MCF-7 (HER2-negative), and MDA-MB-231 (HER2-negative) cells (Figure 4).